The Latest Breaking News from Lilly

2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

Barchart · Nov 21, 2024

Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

International Business Times · Nov 19, 2024

Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan

Eli Lilly is taking the HRSA to court for allegedly blocking the pharma's discount plan.

International Business Times · Nov 15, 2024

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Barchart · Nov 2, 2024

Fact check: Weight loss drug trial, US election rules and ‘IDF soldiers’ image

Round up of fact checks from the last week compiled by Full Fact.

Evening Standard · Oct 24, 2024

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Barchart · Oct 23, 2024

Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to…

StockNews.com · Oct 23, 2024

Alzheimer’s drug rejected for widespread use by NHS spending watchdog

Donanemab is a so-called disease-modifying treatment.

Evening Standard · Oct 23, 2024

Wes Streeting says weight-loss jabs for unemployed not 'dystopian'

THE UK’s Health Secretary has denied his plans to give weight-loss jabs to unemployed people would result in a “dystopian future”.

The National (Scotland) · Oct 20, 2024

Pumping the unemployed with weight-loss drugs echoes Victorian attitudes to the poor

Shifting blame to the victims of economic policy is an old trick by politicians. Now they’re using obesity to tackle joblessness

The Guardian - UK · Oct 20, 2024